Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
